Coloplast A/S (CPH:COLO.B)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 143.88B |
| Revenue (ttm) | 27.79B |
| Net Income (ttm) | 4.54B |
| Shares Out | 225.17M |
| EPS (ttm) | 20.17 |
| PE Ratio | 31.68 |
| Forward PE | 24.59 |
| Dividend | 22.00 (3.44%) |
| Ex-Dividend Date | May 8, 2025 |
| Volume | 253,298 |
| Average Volume | 259,380 |
| Open | 632.60 |
| Previous Close | 640.20 |
| Day's Range | 628.20 - 641.20 |
| 52-Week Range | 628.20 - 959.00 |
| Beta | 0.58 |
| RSI | 29.15 |
| Earnings Date | May 6, 2025 |
About Coloplast
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the B... [Read more]
Financial Performance
In 2024, Coloplast's revenue was 27.03 billion, an increase of 10.33% compared to the previous year's 24.50 billion. Earnings were 5.05 billion, an increase of 5.62%.
Financial StatementsNews
Coloplast A/S 2025 Q1 - Results - Earnings Call Presentation
Coloplast A/S (CLPBF) Q2 2025 Earnings Call Transcript
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Please see enclosed pdf. Attachment 08052025_trading_in_shares_GL
Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H1 2024/25
Interim financial results, H1 2024/25 1 October 2024 - 31 March 2025 Coloplast delivered 6% organic growth in Q2, impacted by the product recall in Interventional Urology and a softer quarter in Ostom...
Coloplast A/S GAAP EPS of DKK4.05, revenue of DKK6.93B
Coloplast Seeks to Restore Investor Trust With Firing of CEO
Coloplast A/S fired its chief executive officer to restore investor confidence after the medical equipment maker failed to deliver sufficient shareholder returns.
Coloplast A/S - Announcement no. 04/2025 - Interim Financial Report, H1 2024/25
Interim financial results, H1 2024/25 1 October 2024 - 31 March 2025 Coloplast delivered 6% organic growth in Q2, impacted by the product recall in Interventional Urology and a softer quarter in Ostom...
Coloplast A/S CEO Kristian Villumsen steps down as of today
Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO.
Coloplast A/S Revised guidance for FY 2024/25
Coloplast revises financial guidance for FY 2024/25 and pre-announces H1 2024/25 key financial figures Coloplast revises the guidance on organic growth and EBIT margin before special items for FY 2024...
Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference call on 6 May 2025 at 11.00am CEST
Tuesday, 6 May 2025 at 11.00 - 12.00am CEST In connection with the publication of Coloplast's interim financial results for H1 2024/25, to be released same day around 07.30am CEST, Coloplast will host...
Coloplast: Cheaper Than In The Past, But Not Yet A Bargain
Coloplast Finance B.V. - Decisions at the Annual General Meeting
On 14 March 2025, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S, approved the annual report for the financial year 2023/24....
Coloplast targets 8%-9% organic growth for FY 2025 amid Kerecis expansion and new launches
Coloplast A/S (CLPBF) Q1 2025 Earnings Call Transcript
Coloplast A/S GAAP EPS of DKK4.63, revenue of DKK7.03B
Coloplast Finance B.V. - Interim Financial Report, Q1 2024/25
2024/25 Interim financial results, Q1 2024/25 1 October 2024 - 31 December 2024 Coloplast delivered 8% organic growth and an EBIT margin1 of 27% in Q1, in line with expectations. Reported revenue in D...
Coloplast A/S - Allocation of Share Options
Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactio...
Coloplast A/S - Interim Financial Report, Q1 2024/25
2024/25 Interim financial results, Q1 2024/25 1 October 2024 - 31 December 2024 Coloplast delivered 8% organic growth and an EBIT margin1 of 27% in Q1, in line with expectations. Reported revenue in D...
3 Top Growth Stocks to Buy and Hold for 2025
The long-term outlooks for these high-quality companies are solid—and their stocks are cheap.
Brett Girard's Past Picks: Coloplast A/S, Telus and Littlefuse
Brett Girard, chief financial officer and portfolio manager at Liberty International Investment Management, discusses his past picks: Coloplast A/S, Telus and Littlefuse.
Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET (correction)
Tuesday, 4 February 2025 at 11.00 - 12.00am CET (corrected from 10.00 - 11.00am CET in an earlier version of this invitation) In connection with the publication of Coloplast's interim financial result...
Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET
Tuesday, 4 February 2025 at 10.00 - 11.00am CET In connection with the publication of Coloplast's interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will h...
Coloplast Still Pricey Even As A High-Quality Med-Tech Growth Name
Analysis of Coloplast's growth potential and concerns for Q1'25, including margin misses and slow share growth in the U.S.
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons.
Coloplast A/S - Decisions at the Annual General Meeting 2024
Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2023/24 was approved. Distribution of y...